N. Feeney

发表

Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.

C. Paweletz, Guocheng Yuan, P. Jänne, 2016, JCI insight.

False-Positive Plasma Genotyping Due to Clonal Hematopoiesis

C. Paweletz, P. Jänne, Kwok-Kin Wong, 2018, Clinical Cancer Research.

Abstract CT046: Phase I dose escalation study of the CDK4/6 inhibitor palbociclib in combination with the MEK inhibitor PD-0325901 in patients withRASmutant solid tumors

C. Paweletz, P. Jänne, Kwok-Kin Wong, 2017 .

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

Suzanne E Dahlberg, Geoffrey R Oxnard, C. Paweletz, 2016, JAMA oncology.

Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer

C. Paweletz, V. Plagnol, Yue-Houng Hu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients

C. Paweletz, J. Garber, J. Odegaard, 2017, Clinical Cancer Research.

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

C. Paweletz, A. Redig, P. Jänne, 2018, JAMA oncology.

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.

G. Mills, M. Ladanyi, C. Paweletz, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

C. Paweletz, A. Redig, P. Jänne, 2016, Clinical Cancer Research.

OA 09.02 Osimertinib Resistance Mediated by Loss of EGFR T790M Is Associated with Early Resistance and Competing Resistance Mechanisms

C. Paweletz, P. Jänne, K. Thress, 2017 .

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.

G. Mills, M. Ladanyi, C. Paweletz, 2019 .

Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib.

C. Paweletz, V. Plagnol, Yuebi Hu, 2017 .

Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR.

C. Paweletz, G. Oxnard, Y. Kuang, 2018, Methods in molecular biology.